4.3 Review

Prostate-specific membrane antigen for the surgical oncologist: interpreting expression beyond the prostate

Journal

ANZ JOURNAL OF SURGERY
Volume 90, Issue 5, Pages 715-718

Publisher

WILEY
DOI: 10.1111/ans.15479

Keywords

general surgery; PSMA; surgical oncology; urology

Categories

Ask authors/readers for more resources

The use of prostate-specific membrane antigen (PSMA) radiotracer in positron emission tomography (PET) has been successfully incorporated into the clinical management of prostate cancer. However, PSMA tracer uptake is not limited to prostate cancer tissue. We reviewed studies exploring PSMA expression beyond the prostate gland using techniques of Ga-68-PSMA PET imaging and immunohistochemistry. PSMA expression has been associated with a variety of solid tumours, and the vasculature associated with neoplastic disease, suggesting that this trans-membrane glycoprotein may be involved in the neovascularisation process in malignancy. These studies demonstrate the need for more research into the potential utility for Ga-68-PSMA PET imaging in patients with non-prostatic cancers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Self-reported lack of energy or feeling depressed 12 months after treatment in men diagnosed with prostate cancer within a population-based registry

Jonathan G. Bensley, Haryana M. Dhillon, Sue M. Evans, Melanie Evans, Damien Bolton, Ian D. Davis, Lachlan Dodds, Mark Frydenberg, Paul Kearns, Nathan Lawrentschuk, Declan G. Murphy, Jeremy L. Millar, Nathan Papa

Summary: Depression and lack of energy are common side effects of prostate cancer and its treatments, with younger men reporting more depressive feelings while men receiving hormonal treatments more commonly experience lack of energy. These symptoms are associated with poorer urinary, bowel, and sexual functional domain scores and clinicians should be aware of their incidence to screen for them, especially in at-risk groups.

PSYCHO-ONCOLOGY (2022)

Review Urology & Nephrology

Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus?

Sean Ong, Kenneth Chen, Jeremy Grummet, John Yaxley, Matthijs J. Scheltema, Phillip Stricker, Kae Jack Tay, Nathan Lawrentschuk

Summary: This article provides a summary and discussion of international guidelines, position statements, and consensus statements on focal therapy for prostate cancer. The lack of long-term randomized data for focal therapy is highlighted, and the need for high-quality clinical trials with robust outcomes is emphasized. The current consensus and position statements are heterogeneous, indicating a need for globally accepted guidelines for focal therapy planning and follow-up.

BJU INTERNATIONAL (2023)

Review Urology & Nephrology

Spontaneous (idiopathic) rupture of the urinary bladder: a systematic review of case series and reports

Deshin Reddy, Abdullah Ebrahim Laher, Nathan Lawrentschuk, Ahmed Adam

Summary: This study conducted a systematic review of all cases of spontaneous rupture of the urinary bladder (SRUB), providing a comprehensive analysis of demographic data, associated comorbidities, clinical presentation, diagnosis, relevant laboratory findings, associated factors, management, morbidity and mortality.

BJU INTERNATIONAL (2023)

Editorial Material Urology & Nephrology

Point-Counterpoint: Active Surveillance in the Real World Has Far More Risks Than We Appreciate

Nathan Lawrentschuk

JOURNAL OF UROLOGY (2023)

Review Oncology

Dysfunctional Lipid Metabolism-The Basis for How Genetic Abnormalities Express the Phenotype of Aggressive Prostate Cancer

Matthew Alberto, Arthur Yim, Nathan Lawrentschuk, Damien Bolton

Summary: Advanced prostate cancer has a higher mortality rate compared to localized prostate cancer, making it crucial to study its development mechanisms and potential pathways for novel treatments. Prostate cancer is the second most common cancer in men, with increasing prevalence due to an aging population. It is important to understand the evolving mechanisms of progression in order to address the significant morbidity and mortality associated with advanced prostate cancer, where treatment options are linked to lipid metabolism.

CANCERS (2023)

Article Urology & Nephrology

Decade-long trends in prostate cancer biopsy grade groups and treatment within a population-based registry

Gavin Wei, Weranja Ranasinghe, Melanie Evans, Damien Bolton, Lachlan Dodds, Mark Frydenberg, Paul Kearns, Nathan Lawrentschuk, Declan G. Murphy, Jeremy Millar, Nathan Papa

Summary: This study retrospectively analyzed patients who underwent prostate biopsy between 2011 and 2020 in the Victorian Prostate Cancer Outcomes Registry. The findings showed a significant decrease in the proportion of GG 1 prostate cancer, especially in younger men. The percentage of interventional management for GG 1 disease also decreased substantially. These results reflect the implementation of major changes in diagnostic and treatment guidelines and provide important insights for future treatment allocation.

BJU INTERNATIONAL (2023)

Review Oncology

New Approaches to Targeting Epigenetic Regulation in Bladder Cancer

Daryl Thompson, Nathan Lawrentschuk, Damien Bolton

Summary: Epigenetic changes are common in urological cancers and have potential as targets for cancer therapy. There have been 25 clinical trials investigating targeted epigenetic therapy in bladder cancer, but no phase 3 trials have been conducted so far. Epigenetics is a rapidly advancing field and holds great promise for the treatment of bladder cancer.

CANCERS (2023)

Editorial Material Urology & Nephrology

Is genetic testing coming of age in advanced prostate cancer?

Kenneth Chen, Sean Ong, Kandarpa Vasundhara, Chow Kit Mun, Isabella Williams, Ravindran Kanesvaran, John Yuen Shyi Peng, Arun A. Azad, Nathan Lawrentschuk

BJU INTERNATIONAL (2023)

Article Urology & Nephrology

Case of the Month from University of Melbourne, Australia: refractory chyle leak after retroperitoneal lymph node dissection with updated algorithm

David C. Homewood, Jonathan S. O'Brien, Todd Manning, Brian Kelly, Philip Chan, Ben Thomas, Nathan Lawrentschuk

BJU INTERNATIONAL (2023)

Editorial Material Urology & Nephrology

The pen is mightier than the machine-artificial intelligence image generators in urology

Siyu Huang, David C. Chen, Jordan Santucci, Declan G. Murphy, Nathan Lawrentschuk

BJU INTERNATIONAL (2023)

Editorial Material Urology & Nephrology

How prostate-specific membrane antigen positron emission tomography is refining risk calculators in the primary prostate diagnostic pathway

Gideon Ptasznik, Brian D. Kelly, Declan Murphy, Nathan Lawrentschuk, Veeru Kasivisvanathan, Mark Page, Sean Ong, Daniel Moon

BJU INTERNATIONAL (2023)

Article Urology & Nephrology

The CONFIRM trial protocol: the utility of prostate-specific membrane antigen positron emission tomography/computed tomography in active surveillance for prostate cancer

Dominic Bagguley, Laurence Harewood, Dean McKenzie, Gideon Ptasznik, Sean Ong, Thilakavathi Chengodu, Dixon Woon, Kenneth Sim, James Sheldon, Nathan Lawrentschuk

Summary: The primary objective of this study is to determine the additional value of PSMA PET/CT in risk stratification and predicting the likelihood of failure in men with newly diagnosed prostate cancer who would have otherwise been suitable for active surveillance. The secondary objectives include determining the value of PSMA PET/CT in comparison to repeat mpMRI, developing a nomogram to predict failure in men with high-risk features, and conducting follow-up studies on molecular biomarkers and genetic assays.

BJU INTERNATIONAL (2023)

Article Urology & Nephrology

Renal cell carcinoma with intra-operatively identified encapsulated intra-luminal tumour extension throughout the entire ureter

Ellen O'Connor, Marcus G. Cumberbatch, Conrad Bishop, Nathan Lawrentschuk

JOURNAL OF CLINICAL UROLOGY (2023)

No Data Available